PressDecember 9, 2022 Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
PressDecember 9, 2022 Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines
PressDecember 9, 2022 Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
PressDecember 9, 2022 The Addition of Three Mental Health Clinics to Irwin Naturals’ Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental Health Clinics
PressDecember 8, 2022 Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects
PressDecember 8, 2022 PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT
PressDecember 8, 2022 Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
PressDecember 8, 2022 Nova Mentis’ Psilocybin Preclinical Study Published in International Science Journal
PressDecember 8, 2022 COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
PressDecember 7, 2022 Red Light Holland’s Wholly Owned Subsidiary, Radix Motion, Receives Favorable International Preliminary Report on Patentability on its Patent Application: Utilizing 3D Movement Data for Psychedelic Therapy
PressDecember 7, 2022 Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December
PressDecember 6, 2022 Enthea Announces Nationwide Rollout to Offer Psychedelic Therapy as a Workplace Benefit
PressDecember 6, 2022 PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
PressDecember 2, 2022 Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
PressDecember 2, 2022 Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
PressNovember 30, 2022 Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
